Sarabjeet Singh Mokha, the accused in the case, is also the Vishwa Hindu Parishad (VHP) president of the Narmada division.
The director of a hospital in Madhya Pradesh’s Jabalpur is among the four people held for procuring and administering fake Remdesivir, a drug used in the treatment of COVID-19 patients, NDTV reported. Sarabjeet Singh Mokha, the accused in the case, is also the Vishwa Hindu Parishad (VHP) president of the Narmada division.
The Director of Jabalpur’s City Hospital Mokha is accused of sourcing 500 vials of the Remdesivir injections from Indorewhich the hospital administered to many COVID-19 patients. The case has been registered against him now under Sections 274, 275, 308, and 420 of the Indian Penal Code.
Among the other accused persons are Devendra Chaurasia, who worked as Mokha’s manager, and Sapan Jain, who handled dealerships with pharmaceutical companies.
The racket was exposed after the Gujarat Police busted a fake Remdesivir manufacturing unit and arrested Jain from Jabalpur on May 7.
Mokha is now relieved of his charges and that the police must take stringent actions against such people, VHP Prant Mantri, Rajesh Tiwari, has said.
Bhagwat Singh, Jabalpur Inspector General, told reporters: “We have recent days set up a nodal officer of the rank of Additional Superintendent of Police, under whose leadership an SIT has been formed to track black marketing of Remdesivir and oxygen. We are trying to break that intricate network.”
“In Chindwara, too, we have caught 3-4 people. Some people in Jabalpur too were caught selling oxygen cylinders ₹ 20,000 for each.”
With India battling the massive second wave of Covid-19, a lot of key resources have been in short supply. Medical oxygen and drugs like Remdesivir are amongst these resources.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
